Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2015 Jun;232(11):1859-66.
doi: 10.1007/s00213-014-3813-x. Epub 2014 Dec 10.

Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey

Joshua D Vardigan  1 , Christopher E Cannon, Vanita Puri, Mandy Dancho, AmyJo Koser, Marion Wittmann, Scott D Kuduk, John J Renger, Jason M Uslaner
Affiliations
Comparative Study

Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey

Joshua D Vardigan et al. Psychopharmacology (Berl). 2015 Jun.

Abstract

Rationale: The standards of care for Alzheimer's disease, acetylcholinesterase inhibitors such as donepezil (Aricept®), are dose-limited due to adverse side-effects. These adverse events lead to significant patient non-compliance, constraining the dose and magnitude of efficacy that can be achieved. Non-selective muscarinic receptor orthosteric agonists such as Xanomeline have been shown to be effective in treating symptoms as well, but were also poorly tolerated. Therefore, there is an unmet medical need for a symptomatic treatment that improves symptoms and is better tolerated.

Methods: We compared donepezil, xanomeline, and the novel selective muscarinic 1 receptor positive allosteric modulator PQCA in combination with donepezil in the object retrieval detour (ORD) cognition test in rhesus macaque. Gastrointestinal (GI) side effects (salivation and feces output) were then assessed with all compounds to determine therapeutic window.

Results: All three compounds significantly reduced a scopolamine-induced deficit in ORD. Consistent with what is observed clinically in patients, both donepezil and xanomeline produced significant GI effects in rhesus at doses equal to or less than a fivefold margin from the minimum effective dose that improves cognition. In stark contrast, PQCA produced no GI side effects when tested at the same dose range.

Conclusions: These data suggest M1 positive allosteric modulators have the potential to improve cognition in Alzheimer's disease with a greater therapeutic margin than the current standard of care, addressing an important unmet medical need.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dement Geriatr Cogn Disord. 2009;28(5):389-403 - PubMed
    1. Alzheimer Dis Assoc Disord. 2008 Jul-Sep;22(3):209-21 - PubMed
    1. FASEB J. 1995 May;9(8):619-25 - PubMed
    1. Life Sci. 2001 Apr 27;68(22-23):2593-600 - PubMed
    1. Alzheimers Dement. 2013 May;9(3):338-45 - PubMed

Publication types

MeSH terms

LinkOut - more resources